Managing Product Supply Risks - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Managing Product Supply Risks
How to use geographic diversification and legacy technology transfers to avoid product shortages.


Pharmaceutical Technology
Volume 36, Issue 4, pp. 102-109

Planning a legacy molecule transfer


Figure 2: Several aspects must be considered in the legacy molecule transfer process.
Once a company makes the decision to transfer a legacy or mature process to a backup manufacturing site, it should consider the key aspects of the process illustrated in Figure 2. A successful technology transfer must have a successful conformance campaign (also referred to as process performance qualification or process validation lots), in which the company demonstrates process consistency and product comparability and gains regulatory licensure. The first and foundational strategy is thus to carefully scope process and method changes and improvements that might affect the success of the conformance campaign. It is generally accepted that the primary and backup manufacturing sites should have the same process chemistry, and that changes should be minimized to avoid process drift. Any process improvements should be deferred to after implementation of the site transfer, and even then should be done in concert between the primary and backup sites to ensure process alignment. Ideally, the process scale should also be kept the same, but in some instance this may be challenging based on facility and equipment constraints and a desire to minimize the capital outlay for such a site-transfer project. Method changes are another concern. If a company decides to use this as an opportunity to remediate and modernize methods, it should allocate sufficient resources and time for these activities. The newer methods may be more sensitive and may reveal the presence of impurities, which, once identified, should be characterized. Care should be taken in changing specifications or process controls, as this could make the site transfer more challenging.

The company should consider several key questions that may impact the scope, cost and timeline for implementing the project and establishing engineering design objectives:

  • Will the secondary facility be used for regular commercial production or purely as a backup?
  • How many lots (i.e., engineering runs) will be required to shake-down the process?
  • How will the process be validated?
  • What is needed to maintain commercial licensure status?

Finally, the company should consider the regulatory landscape. Typically, site transfers are submitted using a prior approval supplement (PAS). Alternate regulatory strategies, such as a comparability protocol or Changes-Being-Effected-30, may be considered, depending on the complexity of the transfer and scope of potential changes. Bundling changes, such as method remediation or specification changes, with the site transfer could increase the complexity and make first-time approval more difficult to obtain. Legacy molecule transfers must deal with the challenge of staying current with evolving regulatory, quality, and operating standards.

The following section describes in more detail a few of the major challenges of legacy molecule transfers and strategies to deal with them.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here